Welcome to our dedicated page for Voyager Therapeutics news (Ticker: $VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Voyager Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Voyager Therapeutics's position in the market.
Voyager Therapeutics, Inc. presented data on second-generation TRACER™-Generated Capsids and CNS Gene Therapy Programs at the ASGCT 27th Annual Meeting. The data showed enhanced blood-brain barrier penetrance, broad CNS biodistribution, and robust transduction of key cell types, supporting the high translational potential of TRACER capsids for gene therapy in the CNS. The company aims to file INDs for three development candidates in neurologic diseases by 2025.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) will report its first quarter 2024 financial and operating results on May 13, 2024. The company will host a conference call and webcast to review the results. Participants can join via telephone or live webcast. Registration is required.
